Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer

NCT04011410 is registered in ClinicalTrials.gov with Patrick Hensley as lead sponsor.

NCT NCT04011410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04011410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer
Lead sponsor
Patrick Hensley
Phase
Phase 2
Overall status
Completed
Start date
December 3, 2019
Completion date
March 8, 2024
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer recurrent